6241-46-9

Usage

InChI:InChI=1/C9H13ClN2/c10-9-4-2-1-3-8(9)7-12-6-5-11/h1-4,12H,5-7,11H2

Upstream product

• 81512-53-0 N,N'-(ethane-1,2-diyl)bis(1-(2-chlorophenyl)methanimine) 
• 611-19-8 1-chloro-2-(chloromethyl)benzene 
• 107-15-3 ethylenediamine 
• 89-98-5 2-chloro-benzaldehyde 
• 622373-33-5 [2-(2-chloro-benzylamino)-ethyl]-carbamic acid tert-butyl ester 
• 100-66-3 methoxybenzene 

Downstream Products

• 61797-03-3 Undec-10-enoic acid (2-chloro-benzyl)-(2-undec-10-enoylamino-ethyl)-amide 
• 69840-63-7 1-(2-chlorobenzyl)-2-(nitromethylene)imidazolidine 
• 6241-45-8 2,7-bis-[2-(2-chlorobenzylamino)ethyl]benzo[lmn][3,8]phenanthroline-1,3,6,8-tetraone 
• 1349396-81-1 C₂₃H₂₆ClN₅O₃ 

Relevant academic research and scientific papers

Design, Synthesis, and Synergistic Activity of Eight-Membered Oxabridge Neonicotinoid Analogues

Insecticide synergists are sought-after due to their potential in improving the pesticide control efficacy with a reduced dose of an active ingredient. We previously reported that a cis-configuration neonicotinoid (IPPA08) exhibited specific synergistic activity toward neonicotinoid insecticides. In this study, we synthesized a series of structural analogues of IPPA08 by converting the pyridyl moiety of IPPA08 into phenyl groups, via facile double-Mannich condensation reactions between nitromethylene compounds and glutaraldehyde. All of the oxabridged neonicotinoid compounds were found to increase the toxicity of imidacloprid against Aphis craccivora. Notably, compound 25 at 0.75 mg/L lowered the LC50 value of imidacloprid against A. craccivora by 6.54-fold, while a 3.50-fold reduction of the LC50 value was observed for IPPA08. The results of bee toxicity test showed that compound 25 display selectivity in its effects on imidacloprid toxicity against the honey bee (Apis mellifera L.). In summary, replacing the pyridyl ring with a phenyl ring was a viable approach to obtain a novel synergist with oxabridged moiety for neonicotinoid insecticides.

Structure-activity relationships of novel substituted naphthalene diimides as anticancer agents

Novel 1,4,5,8-naphthalenetetracarboxylic diimide (NDI) derivatives were synthesized and evaluated for their antiproliferative activity on a wide number of different tumor cell lines. The prototypes of the present series were derivatives 1 and 2 characterized by interesting biological profiles as anticancer agents. The present investigation expands on the study of structure-activity relationships of prototypes 1 and 2, namely, the influence of the different substituents of the phenyl rings on the biological activity. Derivatives 3-22, characterized by a different substituent on the aromatic rings and/or a different chain length varying from two to three carbon units, were synthesized and evaluated for their cytostatic and cytotoxic activities. The most interesting compound was 20, characterized by a linker of three methylene units and a 2,3,4-trimethoxy substituent on the two aromatic rings. It displayed antiproliferative activity in the submicromolar range, especially against some different cell lines, the ability to inhibit Taq polymerase and telomerase, to trigger caspase activation by a possible oxidative mechanism, to downregulate ERK 2 protein and to inhibit ERKs phosphorylation, without acting directly on microtubules and tubuline. Its theoretical recognition against duplex and quadruplex DNA structures have been compared to experimental thermodynamic measurements and by molecular modeling investigation leading to putative binding modes. Taken together these findings contribute to define this compound as potential Multitarget-Directed Ligands interacting simultaneously with different biological targets.

TACHYKININ RECEPTOR ANTAGONISTS

The present invention relates to selective NK-1 receptor antagonists of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykinins.